The DOI matches its Crossref record.
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers
Abstract
The pharmacodynamics of midazolam and its main metabolite alpha-hydroxymidazolam were characterized in individual subjects by use of saccadic eye movement and electroencephalographic (EEG) effect measurements. Eight healthy volunteers received 0.1 mg/kg midazolam intravenously in 15 minutes, 0.15 mg/kg alpha-hydroxymidazolam intravenously in 15 minutes, 7.5 mg midazolam orally and placebo in a randomized, double-blind, four-way crossover experiment. Plasma concentrations of midazolam, alpha-hydroxymidazolam and 4-hydroxymidazolam were measured by gas chromatography. The amplitudes in the 11.5 to 30 Hz (beta) frequency band were used as EEG effect measure. The concentration-effect relationships were quantified by the sigmoid maximum effect model. The median effective concentrations of midazolam and alpha-hydroxymidazolam were (mean +/- SE) 77 +/- 15 and 98 +/- 17 ng/ml, respectively, for the EEG effect measure. For peak saccadic velocity the values were 40 +/- 7 ng/ml for midazolam and 49 +/- 10 ng/ml for alpha-hydroxymidazolam. The maximum effect values were similar for both compounds. The effects observed after oral administration of midazolam could not be predicted accurately by an additive and competitive interaction model. It seems that alpha-hydroxymidazolam is highly potent with respect to the measured effects and contributes significantly to those effects of midazolam after oral administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
Johnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530
Midazolam and Other Benzodiazepines
Olkkola, K. T., & Ahonen, J. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-74806-9_16 · Cited by 488
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Human Variability and Noncancer Risk Assessment— An Analysis of the Default Uncertainty Factor
Renwick, A. G., & Lazarus, N. R. (1998) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1997.1195 · Cited by 261
Danhof, M., de Jongh, J., De Lange, E. C. M., Della Pasqua, O., Ploeger, B. A., & Voskuyl, R. A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105154 · Cited by 258
Self-citationPharmacological treatment effects on eye movement control
Reilly, J. L., Lencer, R., Bishop, J. R., Keedy, S., & Sweeney, J. A. (2008) · Brain and Cognition · doi:10.1016/j.bandc.2008.08.026 · Cited by 248
Lave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960440h · Cited by 184
Induction and maintenance of procedural sedation in adults: focus on remimazolam injection
Chen, W., Chen, S., & Huang, Y. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1901575 · Cited by 25
Remimazolam: an ultrashort-acting intravenous anesthetic suitable for general anesthesia
CARDIA, L. (2021) · Minerva Anestesiologica · doi:10.23736/s0375-9393.21.16006-7 · Cited by 16
Metadata
- Authors
- Mandona, J. W., Tuk, B., van Steveninck, A. L., Breimer, D. D., Cohen, A. F., & Danhof, M.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1992-06
- Volume
- 51
- Issue
- 6
- Pages
- 715-728
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2012293219
- Cited by
- 229
- References
- 0
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.